Literature DB >> 25394504

Knockdown of EGFR inhibits growth and invasion of gastric cancer cells.

Y Zhen1, L Guanghui1, Z Xiefu1.   

Abstract

The epidermal growth factor receptor (EGFR) is an oncogenic trans-membranous receptor, which is overexpressed in multiple human cancers. However, the role of EGFR in gastric cancer (GC) is still elusive. In this study, we aimed to investigate the expression and molecular mechanisms of EGFR in GC cells. Forty cases of GC and the corresponding adjacent non-cancerous tissues (ANCT) were collected, and the expression of EGFR was assessed using immunohistochemistry in biopsy samples. Furthermore, EGFR signaling was blocked by constructed recombinant small hairpin RNA lentiviral vector (Lv-shRAGE) used to transfect into human GC SGC-7901 cells. The expression of AKT, proliferating cell nuclear antigen (PCNA) and matrix metallopeptidase-9 (MMP-9) was detected by real-time PCR and western blotting assays. Cell proliferative activities and invasive capability were, respectively, determined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) and Transwell assays. Cell apoptosis and cycle distribution were analyzed by flow cytometry. EGFR was found highly expressed in cancer tissues compared with the ANCT and correlated with lymph node metastases. Knockdown of EGFR reduced cell proliferation and invasion of GC with decreased expression of AKT, PCNA and MMP-9 and induced cell apoptosis and cycle arrest. Upregulation of EGFR expression is associated with lymph node metastases of GC, and blockade of EGFR signaling suppresses growth and invasion of GC cells through AKT pathway, suggesting that EGFR may represent a potential therapeutic target for this aggressive malignancy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394504     DOI: 10.1038/cgt.2014.55

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  39 in total

Review 1.  SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review.

Authors:  Abbas Agaimy; Tilman T Rau; Arndt Hartmann; Robert Stoehr
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

2.  Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.

Authors:  B Ye; L-L Jiang; H-T Xu; D-W Zhou; Z-S Li
Journal:  Int J Immunopathol Pharmacol       Date:  2012 Jul-Sep       Impact factor: 3.219

3.  MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer.

Authors:  Gang Liu; Chuanshen Jiang; Dazhou Li; Rong Wang; Wen Wang
Journal:  Tumour Biol       Date:  2014-07-01

4.  New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice.

Authors:  Akihiro Ito; Yuichi Ito; Shigeru Matsushima; Daisuke Tsuchida; Mai Ogasawara; Junichi Hasegawa; Kazunari Misawa; Eisaku Kondo; Norio Kaneda; Hayao Nakanishi
Journal:  Gastric Cancer       Date:  2013-11-28       Impact factor: 7.370

Review 5.  Molecular pathways: HER3 targeted therapy.

Authors:  Kinisha Gala; Sarat Chandarlapaty
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

6.  HER2 aberrations in cancer: implications for therapy.

Authors:  Min Yan; Barbara A Parker; Richard Schwab; Razelle Kurzrock
Journal:  Cancer Treat Rev       Date:  2014-03-12       Impact factor: 12.111

7.  miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression.

Authors:  Juan Xie; Ming Chen; Jing Zhou; Ming-Shu Mo; Li-Hui Zhu; Yan-Ping Liu; Qing-Jun Gui; Li Zhang; Guo-Qing Li
Journal:  Oncol Rep       Date:  2014-02-24       Impact factor: 3.906

8.  Activation of EGFR and ERBB2 by Helicobacter pylori results in survival of gastric epithelial cells with DNA damage.

Authors:  Rupesh Chaturvedi; Mohammad Asim; M Blanca Piazuelo; Fang Yan; Daniel P Barry; Johanna Carolina Sierra; Alberto G Delgado; Salisha Hill; Robert A Casero; Luis E Bravo; Ricardo L Dominguez; Pelayo Correa; D Brent Polk; M Kay Washington; Kristie L Rose; Kevin L Schey; Douglas R Morgan; Richard M Peek; Keith T Wilson
Journal:  Gastroenterology       Date:  2014-02-13       Impact factor: 22.682

9.  EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?

Authors:  Rossella Terragni; Andrea Casadei Gardini; Silvia Sabattini; Giuliano Bettini; Dino Amadori; Chiara Talamonti; Massimo Vignoli; Laura Capelli; Jimmy H Saunders; Marianna Ricci; Marianna Ricci; Paola Ulivi; Paola Ulivi
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

10.  Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a.

Authors:  Er-bao Zhang; Rong Kong; Dan-dan Yin; Liang-hui You; Ming Sun; Liang Han; Tong-peng Xu; Rui Xia; Jin-song Yang; Wei De; Jin fei Chen
Journal:  Oncotarget       Date:  2014-04-30
View more
  10 in total

1.  Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling.

Authors:  Sirichat Kaowinn; Seung Won Jun; Chang Seok Kim; Dong-Myeong Shin; Yoon-Hwae Hwang; Kyujung Kim; Bosung Shin; Chutima Kaewpiboon; Hyeon Hee Jeong; Sang Seok Koh; Oliver H Krämer; Randal N Johnston; Young-Hwa Chung
Journal:  Cell Oncol (Dordr)       Date:  2017-08-03       Impact factor: 6.730

2.  E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line.

Authors:  Erin Isaacson Wechsler; Sharof Tugizov; Rossana Herrera; Maria Da Costa; Joel M Palefsky
Journal:  J Gen Virol       Date:  2018-04-06       Impact factor: 3.891

3.  The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer.

Authors:  C J Wang; P J Tong; M Y Zhu
Journal:  Clin Transl Oncol       Date:  2015-09-14       Impact factor: 3.405

4.  EGF-reduced Wnt5a transcription induces epithelial-mesenchymal transition via Arf6-ERK signaling in gastric cancer cells.

Authors:  Yujie Zhang; Jun Du; Jianchao Zheng; Jiaojing Liu; Rui Xu; Tian Shen; Yichao Zhu; Jun Chang; Hong Wang; Zhihong Zhang; Fanqing Meng; Yan Wang; Yongchang Chen; Yong Xu; Luo Gu
Journal:  Oncotarget       Date:  2015-03-30

5.  13-Methyl-palmatrubine induces apoptosis and cell cycle arrest in A549 cells in vitro and in vivo.

Authors:  Jingxian Chen; Xingang Lu; Chenghua Lu; Chunying Wang; Haizhu Xu; Xiaoli Xu; Haixin Gou; Bing Zhu; Wangchun Du
Journal:  Oncol Rep       Date:  2016-09-15       Impact factor: 3.906

6.  MicroRNA‑509 acts as a tumor suppressor in tongue squamous cell carcinoma by targeting epidermal growth factor receptor.

Authors:  Chao Hou; Yan Dong; Fenghe Zhang; Bo Du
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

7.  Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells.

Authors:  Katarzyna Pietraszek-Gremplewicz; Aleksandra Simiczyjew; Ewelina Dratkiewicz; Marta Podgórska; Ilona Styczeń; Rafał Matkowski; Marcin Ziętek; Dorota Nowak
Journal:  J Cell Mol Med       Date:  2019-10-22       Impact factor: 5.310

Review 8.  The Molecular Roles and Clinical Implications of Non-Coding RNAs in Gastric Cancer.

Authors:  Yanping Yue; Xinrong Lin; Xinyue Qiu; Lei Yang; Rui Wang
Journal:  Front Cell Dev Biol       Date:  2021-12-13

9.  Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.

Authors:  Swathi V Iyer; Alejandro Parrales; Priya Begani; Akshay Narkar; Amit S Adhikari; Luis A Martinez; Tomoo Iwakuma
Journal:  Oncotarget       Date:  2016-02-02

10.  CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells.

Authors:  Wenjie Deng; Luo Gu; Xiaojie Li; Jianchao Zheng; Yujie Zhang; Biao Duan; Jie Cui; Jing Dong; Jun Du
Journal:  J Transl Med       Date:  2016-02-01       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.